Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn’s Disease Comparing, between CT-P13 and Originator Infliximab

Background/Aims: The clinical efficacy and safety of CT-P13 are comparable to originator infliximab for Crohn’s disease in CT-P13 3.4 study (NCT02096861). We performed a multivariate logistic analysis to demonstrate the association between early infliximab trough levels and treatment outcomes of CT-...

Full description

Bibliographic Details

Published in:	Gut and Liver
Main Authors:	Jihye Park, Jae Hee Cheon, Kang-Moon Lee, Young-Ho Kim, Byong Duk Ye, Chang Soo Eun, Sung Hyun Kim, Sun Hee Lee, Joon Ho Lee, Stefan Schreiber
Format:	Article
Language:	English
Published:	Gastroenterology Council for Gut and Liver 2023-05-01
Subjects:	ct-p13 crohn disease infliximab trough level immunogenicity
Online Access:	http://gutnliver.org/journal/view.html?doi=10.5009/gnl220005